Abituzumab

Abituzumab (DI17E6) is a humanised anti-integrin αV monoclonal antibody (IgG2 type). Abituzumab effectively reduces the phosphorylation of FAK, Akt and ERK. Abituzumab can be used in cancer research, particularly in prostate cancer[1].

Research Areas >> Cancer

Signaling Pathways >> Cytoskeleton >> Integrin

Integrin αV[1].

Abituzumab (DI17E6) (0.01, 0.1, 1, 10, 30,100 µg/mL; 24 h) inhibits adhesion of PCa cells to multiple extracellular matrix proteins but not collagen I[1] Abituzumab (100 µg/mL; 12, 18 h) inhibits inhibits motility and invasion of PCa cells[1]. Abituzumab (0.01, 0.1, 1, 10, 30,100 µg/mL; 24 h) inhibits the ability of PCa cells to adhere to osteoblast and bone stromal cell lines[1]. Abituzumab (100 µg/mL; 24 h) blocks integrin-mediated cell signaling in PCa cancer cell lines[1]. Cell Viability Assay[1] Cell Line: PCa cells Concentration: 0.01, 0.1, 1, 10, 30,100 µg/mL Incubation Time: 24 h Result: Promoted detachment of PCa cells from vitronectin (up to approximately 20% cells detached at 100 μg/mL), osteopontin (up to approximately 10% cells detached at 100 μg/mL) and fibronectin (up to approximately 10% cells detached at 100 μg/mL) but not from collagen I. Cell Invasion Assay[1] Cell Line: PCa cells Concentration: 100 µg/mL Incubation Time: 12, 18 h Result: Inhibited invasive ability by approximately 25 to 30% compared to vehicle, and inhibited motility by approximately 30 to 40%. Cell Viability Assay[1] Cell Line: PCa, hFOB, Saos2, HS-5, HDMEC cells Concentration: 0.01, 0.1, 1, 10, 30,100 µg/mL Incubation Time: 24 h Result: Inhibited PCa cells adhesion to human osteoblast cell lines hFOB and Saos2 and a bone marrow stromal cell line, HS-5. Promoted detachment of PCa cells from to a known expressor of αv integrins, HDMEC cells. Western Blot Analysis[1] Cell Line: PC3, DU145, C4-2B, LNCaP, ARCaP and VCaP cells Concentration: 100 µg/mL Incubation Time: 24 h Result: Inhibited FAK phosphorylation starting at 12 h and 6 h in C4-2B and LNCaP, respectively; AKT phosphorylation starting at 3 h and 2 h in C4-2B and LNCaP, respectively; and ERK phosphorylation at starting at 1 h and 1.5 h in C4-2B and LNCaP, respectively.

[1]. Jiang Y, et al. Abituzumab Targeting of αV-Class Integrins Inhibits Prostate Cancer Progression. Mol Cancer Res. 2017 Jul;15(7):875-883.